ISCT

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Retrieved on: 
Wednesday, March 13, 2024
ICST, ISCT, International Society, Disease, Science, Career Achievement Award, Patient, Knowledge, Lead, Gene, University College London, GMP, CGT, CSO, Vaccine

Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.

Key Points: 
  • The award was announced as part of the annual ICST Major Awards announcement.
  • Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
  • The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
  • “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.

Multiply Labs Unveils First Peer-Reviewed Study Showing that Robotic Cell Expansion Can Match the Performance and Reduce the Costs of a Manual Process

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Health Technology, Technology, Manufacturing, Automation, Multiplication, Patient, GMP, Cell, Multimedia, Therapy, Organization, ISCT, FDA, Phenotype, International Society, Medical device

View the full release here: https://www.businesswire.com/news/home/20240326888217/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240326888217/en/
    The paper, “ Development of a robotic cluster for automated and scalable cell therapy manufacturing ,” found that during the expansion phase of T cells-based therapy, Multiply Labs’ robotic system can automate an existing manual process while maintaining statistical equivalence on all critical process parameters.
  • In fact, as much as 50% of manufacturing costs stem from labor-intensive manual processes and a shortage of skilled workers.
  • A key advantage of Multiply Labs’ robotic technology is its compatibility with leading cell therapy manufacturing instruments.
  • The data in this study shows that it is possible to automate an existing cell expansion protocol without significantly changing the process or impacting product characteristics.

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Retrieved on: 
Monday, August 14, 2023
Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Science, Clinical Trials, CMS, Center for Medicare and Medicaid Innovation, MBA, Medicare, Patient, Data, Transplant, FOXO1, Cell, National Lottery Community Fund, York Capital Management, Morgan Stanley, Therapy, Gene, Defense, Department of Defence, NK, NAM, Oxidative stress, FDA, Centers for Medicare & Medicaid Services, Non-Hodgkin lymphoma, Veteran, ATM, United States Department of Veterans Affairs, Documentation, NMDP, International Society, Science Translational Medicine, Insightec, National Marrow Donor Program, Medicaid, Partnership, ISCT, Thomas Jefferson University, Annual general meeting, CD62L, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Health insurance, Dentistry, Management, Cryptocurrency, IIA

(Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended June 30, 2023.
  • “Since the approval of Omisirge in April, Gamida Cell has made excellent progress on the launch,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • Terry Coelho, MBA, appointed Chief Financial Officer: In May 2023, Gamida Cell announced the appointment of Terry Coelho as Chief Financial Officer.
  • Commercial expenses were $3.9 million in the second quarter of 2023, compared to $3.2 million in the second quarter of 2022.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, Paris

Retrieved on: 
Monday, June 5, 2023
Research, Genetics, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Karolinska Institute, Nobel Prize, CRISPR, Vinnova, Nobel Assembly at the Karolinska Institute, Therapy, HLA, ISCT, Integration competency center, NK, Hepatocyte, Stem cell, II, Risk, Rejection, Engineering, Cancer, Cell, 2022 Nobel Prize in Physiology or Medicine, KI, International Society, Vaccine, Medical device, Medicine, Physiology

The VY-UC Abstract was recently published in a supplemental version of Cytotherapy (Volume 25, Issue 6 Supplement, S13-S14, May 2023) the official journal of ISCT: https://www.isct-cytotherapy.org/article/S1465-3249(23)00148-2/fulltext .

Key Points: 
  • The VY-UC Abstract was recently published in a supplemental version of Cytotherapy (Volume 25, Issue 6 Supplement, S13-S14, May 2023) the official journal of ISCT: https://www.isct-cytotherapy.org/article/S1465-3249(23)00148-2/fulltext .
  • A: “The goal for engineering any allogeneic cell is to overcome the risk that the patient’s immune system will recognize and eliminate the donor-sourced foreign cells.
  • Unfortunately, allogeneic cell therapy studies to date do not appear to yet match up to the outcomes achieved by autologous products, especially when measuring cell persistence and durable outcomes.
  • For more information, please visit: www.Vycellix.com and follow our Twitter feed at: @Vycellix.

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Retrieved on: 
Thursday, June 1, 2023
ASC, CRISPR, CELU, Placenta, Gene, Thrombogenicity, Diabetic foot ulcer, ISCT, Immunomodulation, Instituto de Biologia Molecular e Celular, Cell, Multiple sclerosis, FSHD, Stem cell, Microsoft Exchange Server, Thrombosis, MSC, Facioscapulohumeral muscular dystrophy, TF, Data, Blood, Abdominal ultrasonography, Phenotype, International Society, Safety, Pharmaceutical industry, Vaccine, Cytotherapy

FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT).

Key Points: 
  • The paper, “Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects,” (Huang, et al.
  • )1 examined methods to reduce the tissue factor expressed by allogeneic stromal cells (ASCs), which has been regarded as a safety concern in clinical applications as it may trigger thrombosis when ASCs are administered intravenously.
  • Thrombogenic risk has been identified in association with intravenous administration of mesenchymal stem cells (MSCs), both allogeneic and autologous.
  • These cells express procoagulant activity linked to the expression of tissue factor that, when in contact with blood, initiates coagulation.

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
MYT, ISCT, MAGE-A1, Neoplasm, Clinical trial, Cancer, TCR, Patient, SAN, Superior, Annual general meeting, Cell, Mouse, Therapy, International Society, Vaccine

“These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.

Key Points: 
  • “These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.
  • “Specifically, leveraging our MyT platform, we isolated TK 8001, a naturally optimized high-affinity TCR specific for the cancer testis antigen MAGE-A1.
  • TK-8001, has repeatedly demonstrated superior in vitro anti-tumor activity against cancer cell lines derived from a wide range of tumors and superior in vivo anti-tumor activity in a very challenging syngeneic tumor mouse model.”
    MAGE-A1-specific TCRs were isolated from MyT platform mice immunized with the MAGE-A1 epitope.
  • Human donor-derived TCRs reactive to the same epitope were synthesized based on publicly available sequences, including a clinical-stage TCR.

BioCentriq® Launches LEAP™ Advanced Therapy Platform with Proven Assets and Expertise that Help Early-Stage BioTech Companies Reach Patients in Record Time

Retrieved on: 
Thursday, June 1, 2023
Pressure, CDMO, International Society, ISCT, Cell, Pharmaceutical industry

NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.

Key Points: 
  • NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.
  • "In the current economic environment, biotech companies with promising candidates are under greater pressure than ever to demonstrate results quickly," said Haro Hartounian, Ph.D. and CEO and Founder of BioCentriq.
  • "The LEAP™ platform is designed to help early-stage biotech companies prioritize speed in a very calculated and conscientious manner without compromising quality or introducing unnecessary risks."
  • The LEAP™ advanced therapy platform utilizes pre-existing assets and expertise to reduce process development and scale-up timelines by up to 75%.

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Retrieved on: 
Wednesday, May 31, 2023
Macrophage, ISCT, Immunotherapy, ID, CELL, Cell, AN, Poster, Therapy, International Society, Vaccine

Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster presentations, including a selected Elevator Pitch Presentation at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy (ISCT), which is taking place from May 31, 2023 through June 03, 2023 in Paris, France.

Key Points: 
  • Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster presentations, including a selected Elevator Pitch Presentation at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy (ISCT), which is taking place from May 31, 2023 through June 03, 2023 in Paris, France.
  • The poster (ID#805) presentation, “DEVELOPMENT OF A FROZEN FORMULATION OF ALLOCETRA-OTS, AN INNOVATIVE MACROPHAGE REPROGRAMMING CELL-BASED THERAPY”, which details the development and regulatory acceptance of Allocetra frozen formulation, was selected for presentation at the Elevator Pitch Session on Wednesday, May 31, 2023 from 7:00 PM to 8:00 PM CEST, session room 241.
  • The second poster (ID#1003) presentation, “IN VITRO BIOLOGICAL ACTIVITY CHARACTERIZATION AND CELL BASED POTENCY ASSAY DEVELOPMENT FOR ALLOCETRA OTS”, will take place on June 1, 2023 from 6:00 PM to 7:30 PM CEST.
  • The third poster (ID#1057) presentation, “SYNERGISTIC PERITONEAL ANT-TUMOR EFFECT OF ALLOCETRA-OTS, A CELLULAR IMMUNE THERAPY , IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS/CHEMOTHERAPY THROUGH REPROGRAMMING OF MACROPHAGES AND DENDRITIC CELLS”, will take place on June 1, 2023 from 6:00 PM to 7:30 PM CEST.

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, CD161, Therapy, TNF, Gene, ISCT, HER2, CD57, NK, TRAIL, Cell, NAM, CAR, Apoptosis, Annual general meeting, CD62L, Meditation, Phenotype, International Society, Pharmaceutical industry, Vaccine, Fine chemical

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell’s investigational natural killer (NK) cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell’s investigational natural killer (NK) cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting.
  • Additionally, a poster will be presented with data from Gamida Cell’s pre-clinical NK cell therapy candidate GDA-501, an engineered intrinsic NK cell with a CAR modification targeting the HER2 protein.
  • Compared with non-engineered NK cells cultured with NAM, GDA-501 cells displayed increased cytotoxicity against HER2+ tumor cells.
  • Note: Gamida Cell announced it would discontinue the development of GDA-501 in March 2023.